Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Generic DrugsDiabetesBiologicsBiosimilar

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798352

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1798352

Basal Insulin

PUBLISHED:
PAGES: 179 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Basal Insulin Market to Reach US$322.2 Million by 2030

The global market for Basal Insulin estimated at US$265.5 Million in the year 2024, is expected to reach US$322.2 Million by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Lantus Insulin, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$101.9 Million by the end of the analysis period. Growth in the Levemir Insulin segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$72.3 Million While China is Forecast to Grow at 5.9% CAGR

The Basal Insulin market in the U.S. is estimated at US$72.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$63.1 Million by the year 2030 trailing a CAGR of 5.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Basal Insulin Market - Key Trends & Drivers Summarized

How Are Shifting Treatment Paradigms Influencing the Use of Basal Insulin in Diabetes Care?

The landscape of diabetes management has been undergoing significant transformation, and basal insulin continues to play a central role in these evolving treatment paradigms. Designed to provide a steady release of insulin over a prolonged period, basal insulin supports glucose control in both type 1 and type 2 diabetes by mimicking the body’s natural background insulin secretion. While newer therapies such as GLP-1 receptor agonists and SGLT2 inhibitors are gaining attention, basal insulin remains a cornerstone in glycemic management, especially for patients who fail to achieve targets with oral antidiabetic drugs alone. In clinical practice, physicians increasingly emphasize early initiation of basal insulin to prevent complications related to prolonged hyperglycemia. Modern basal insulin analogs like insulin glargine, insulin detemir, and insulin degludec offer more predictable pharmacokinetics, reduced risk of nocturnal hypoglycemia, and improved adherence due to once-daily dosing. Additionally, the recognition of diabetes as a progressive condition has shifted treatment goals toward individualized care, where basal insulin is frequently integrated as part of combination regimens tailored to patient-specific needs. The growing burden of type 2 diabetes worldwide, particularly in aging populations and those with sedentary lifestyles, reinforces the ongoing demand for basal insulin therapy as part of a multifaceted approach to long-term metabolic control.

Why Are Advancements in Formulation and Delivery Systems Enhancing Basal Insulin Adoption?

Technological progress in formulation science and insulin delivery systems is significantly enhancing the adoption and usability of basal insulin across diverse patient populations. Next-generation basal insulin analogs are being engineered for ultra-long action profiles, offering extended glucose control beyond 24 hours with minimal fluctuations in blood sugar levels. This has proven particularly beneficial for patients with irregular schedules or those who face challenges with rigid medication timing. Improved formulation stability and lower injection site variability are also contributing to more consistent therapeutic outcomes. On the delivery front, the rise of user-friendly insulin pens and digital injection tracking tools is making insulin administration more accessible and less intimidating for newly diagnosed patients. These innovations reduce the cognitive and psychological barriers to insulin initiation, a factor often associated with delayed treatment intensification. In parallel, mobile health applications and glucose monitoring technologies now support tighter integration of basal insulin dosing with real-time data insights, helping patients and healthcare providers make more informed treatment adjustments. Biosimilar versions of basal insulin have also entered the market, offering cost-effective alternatives without compromising quality or efficacy, thus expanding access in both developed and emerging healthcare systems. These ongoing innovations in both product design and user experience are making basal insulin not only more effective but also more approachable for the growing global diabetic population.

How Are Health Policy, Market Access, and Patient Education Shaping the Global Basal Insulin Market?

Health policy reforms, reimbursement mechanisms, and patient education efforts are playing critical roles in shaping access and adherence to basal insulin therapies globally. In many high-income countries, insurance coverage and national health plans increasingly support the use of long-acting basal insulins as first-line injectable therapy for type 2 diabetes when oral medications are insufficient. Policies aimed at reducing the economic burden of diabetes are facilitating wider adoption of biosimilar insulin analogs, which offer similar therapeutic benefits at a lower cost. In lower-income settings, however, access remains a challenge due to affordability issues and limited healthcare infrastructure. Global health organizations and non-profits are working to close this gap by negotiating pricing agreements and providing supply chain support to ensure that insulin reaches underserved populations. Alongside access efforts, education initiatives are gaining traction to address insulin hesitancy, particularly among type 2 diabetes patients who often delay insulin initiation due to fears of injections, hypoglycemia, or perceived treatment failure. Empowering patients with accurate information and support from diabetes educators is key to improving early adoption and adherence. As countries integrate digital health tools into their public health strategies, virtual care and telemedicine are being leveraged to guide patients through basal insulin titration and monitor long-term outcomes, thereby boosting confidence in insulin use and enhancing overall diabetes control at a population level.

What Is Driving the Growth of the Global Basal Insulin Market?

The growth in the global basal insulin market is being driven by a combination of epidemiological trends, technological advancements, and strategic market developments. The rising global prevalence of diabetes, particularly type 2 diabetes, is the most prominent factor fueling demand, with lifestyle factors such as obesity, sedentary behavior, and aging populations contributing significantly to this surge. In response to this growing burden, healthcare systems are prioritizing the early initiation and long-term optimization of insulin therapy, especially basal insulin, due to its proven efficacy in achieving and maintaining glycemic targets. The launch of novel insulin analogs with improved pharmacodynamic properties, such as flatter action profiles and longer durations, is attracting both clinicians and patients seeking more convenient and effective options. In addition, the increasing availability of biosimilar basal insulins is expanding treatment access while intensifying competition among manufacturers, leading to better affordability and broader market penetration. Partnerships between pharmaceutical companies and digital health platforms are also creating integrated diabetes management ecosystems that support patient adherence and real-world outcome tracking. Growth is further supported by expanding diagnosis rates in emerging markets, where urbanization and healthcare investment are increasing patient reach. Altogether, these drivers are establishing a robust and sustainable trajectory for the basal insulin market, ensuring it remains a vital component of global diabetes care for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Basal Insulin market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin, Basaglar Insulin)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • Adocia
  • Biocon Limited
  • Boehringer Ingelheim
  • Dongbao Enterprise Group
  • Eli Lilly and Company
  • Gan & Lee Pharmaceuticals
  • Geropharm
  • Glenmark Pharmaceuticals
  • Julphar (Gulf Pharmaceutical Industries)
  • Merck KGaA (EMD Serono in US/Canada)
  • Mylan N.V. (part of Viatris)
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A.
  • Sandoz (a Novartis division)
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Wockhardt Ltd.
  • Ypsomed Holding AG
  • Zhuhai United Laboratories Co., Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP38555

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Basal Insulin - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Long-Acting Insulin Therapies
    • Shifting Treatment Protocols Spur Demand for Simplified Basal Insulin Regimens
    • Aging Population and Higher Type 2 Diabetes Incidence Expand Addressable Market for Basal Insulin
    • Technological Innovations in Insulin Formulations Strengthen Business Case for Next-Gen Basal Products
    • Growing Emphasis on Glycemic Control with Fewer Hypoglycemia Risks Drives Adoption of Advanced Basal Insulin
    • Here's How Patient-Centric Delivery Devices Accelerate Demand in Home-Based Diabetes Management
    • Health System Pressures to Lower Total Cost of Care Propel Use of Long-Acting Insulin in Public Programs
    • Rising Awareness and Diagnosis Rates Sustain Growth in Underserved and Rural Markets
    • Inclusion of Basal Insulin in National Formularies Expands Market Penetration in Emerging Economies
    • Increasing Use in Combination Therapies Throws the Spotlight on Basal Insulin as a Foundational Treatment
    • Here's the Story: How Biosimilar Basal Insulin is Reshaping Competitive Dynamics and Pricing Models
    • Digital Health Integration with Insulin Delivery Devices Generates Demand for Smart Basal Insulin Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Basal Insulin Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Basal Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lantus Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lantus Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Lantus Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Levemir Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Levemir Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Levemir Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Toujeo Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Toujeo Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Toujeo Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tresiba Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tresiba Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tresiba Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Basaglar Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Basaglar Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Basaglar Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • JAPAN
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • CHINA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: China 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • EUROPE
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Basal Insulin by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • FRANCE
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: France 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • GERMANY
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Basal Insulin by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • INDIA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: India 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Basal Insulin by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Basal Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Basal Insulin by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Basal Insulin by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030
  • AFRICA
    • Basal Insulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Basal Insulin by Product - Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Basal Insulin by Product - Percentage Breakdown of Value Sales for Lantus Insulin, Levemir Insulin, Toujeo Insulin, Tresiba Insulin and Basaglar Insulin for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!